Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer
Dr Do-Youn Oh speaks to ecancer about the TOPAZ-1 phase III trial at interim analysis. This trial showed that durvalumab, in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC). Dr Oh says that patients with advanced biliary tract cancer are in dire need of new treatments as progress in the 1st-line setting has remained largely stagnant for more than 10 years. TOPAZ-1 is the first phase III trial to show that adding an immunotherapy to standard chemotherapy delivers a meaningful overall survival benefit for patients in this setting. Dr Oh discusses the important results of this trial. She says the combination also demonstrated an improvement in progression-free survival (PFS) and overall response rate, key secondary endpoints. Durvalumab plus chemotherapy was well tolerated, had a similar safety profile versus the comparator arm and did not increase the discontinuation rate due to adverse events compared to chemotherapy alone.ย
She concludes by saying these results are a major step forward in treating this disease and represent new hope for our patients.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
No comments found